Xiao-Zhou He1, Liang Wang, Yan-Yun Zhang. 1. Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.
Abstract
AIM: To investigate the effect of a vaccine with recombinant adenovirus interleukin-12 (AdVIL-12) transduced dendritic cells (DCs) against colon cancer in mice. METHODS: DCs and AdVIL-12 were incubated together at different time intervals and at different doses. Supernatant was collected and tested for IL-12 by enzyme-linked immunosorbent assay (ELISA). In order to determine whether tumor cell lysate-pulsed (TP) AdVIL-12/DCs enhance therapeutic potential in the established tumor model, CT26 colon tumor cells were implanted subcutaneously (s.c.) in the midflank of naive BALB/c mice. Tumor-bearing mice were injected with a vaccination of CT26 TP AdVIL-12/DCs on d 3 and 10. As a protective colon tumor model, naive BALB/c mice were immunized s.c. in their abdomens with CT26 TP AdVIL-12/DCs twice at seven day intervals. After the immunization on d 7, the mice were challenged with a lethal dose of CT26 tumor cells and survival times were evaluated. Subsequently, cytotoxic T lymphocyte (CTL) activity and interferon gamma (IFNgamma) secretion was evaluated in the immunized mice, and assayed CTL ex vivo. RESULTS: Murine DCs were retrovirally transduced with AdVIL-12 efficiency, and the AdVIL-12 transduced DCs secreted a high level of IL-12 (AdVIL-12/DCs, 615.27+/-42.3 pg/mL vs DCs, 46.32+/-7.29 pg/mL, P<0.05). Vaccination with CT26 TP AdVIL-12/DCs could enhance anti-tumor immunity against CT26 colon tumor in murine therapeutic models (tumor volume on d 19: CT26 TP AdVIL-12/DCs 107+/-42 mm3 vs CT26 TP DCs 383+/-65 mm3, P<0.05) and protective models. Moreover, the CT26 TP AdVIL-12/DC vaccination enhances tumor-specific CTL activity, producing high levels of IFNgamma in immunized mice. Ex vivo primed T cells with AdVIL-12/DCs were able to induce more effective CTL activity than in primed T cells with CT26 TP/DCs (E:T=100:1, 69.49%+/-6.11% specific lysis vs 37.44%+/-4.32% specific lysis, P<0.05). CONCLUSION: Vaccination with recombinant AdVIL-12 transduced DC pulsed tumor cell lysate enhance anti-tumor immunity specific to colon cancer in mice.
AIM: To investigate the effect of a vaccine with recombinant adenovirus interleukin-12 (AdVIL-12) transduced dendritic cells (DCs) against colon cancer in mice. METHODS: DCs and AdVIL-12 were incubated together at different time intervals and at different doses. Supernatant was collected and tested for IL-12 by enzyme-linked immunosorbent assay (ELISA). In order to determine whether tumor cell lysate-pulsed (TP) AdVIL-12/DCs enhance therapeutic potential in the established tumor model, CT26colon tumor cells were implanted subcutaneously (s.c.) in the midflank of naive BALB/c mice. Tumor-bearing mice were injected with a vaccination of CT26TP AdVIL-12/DCs on d 3 and 10. As a protective colon tumor model, naive BALB/c mice were immunized s.c. in their abdomens with CT26TP AdVIL-12/DCs twice at seven day intervals. After the immunization on d 7, the mice were challenged with a lethal dose of CT26tumor cells and survival times were evaluated. Subsequently, cytotoxic T lymphocyte (CTL) activity and interferon gamma (IFNgamma) secretion was evaluated in the immunized mice, and assayed CTL ex vivo. RESULTS:Murine DCs were retrovirally transduced with AdVIL-12 efficiency, and the AdVIL-12 transduced DCs secreted a high level of IL-12 (AdVIL-12/DCs, 615.27+/-42.3 pg/mL vs DCs, 46.32+/-7.29 pg/mL, P<0.05). Vaccination with CT26TP AdVIL-12/DCs could enhance anti-tumor immunity against CT26colon tumor in murine therapeutic models (tumor volume on d 19: CT26TP AdVIL-12/DCs 107+/-42 mm3 vs CT26 TP DCs 383+/-65 mm3, P<0.05) and protective models. Moreover, the CT26TP AdVIL-12/DC vaccination enhances tumor-specific CTL activity, producing high levels of IFNgamma in immunized mice. Ex vivo primed T cells with AdVIL-12/DCs were able to induce more effective CTL activity than in primed T cells with CT26 TP/DCs (E:T=100:1, 69.49%+/-6.11% specific lysis vs 37.44%+/-4.32% specific lysis, P<0.05). CONCLUSION: Vaccination with recombinant AdVIL-12 transduced DC pulsed tumor cell lysate enhance anti-tumor immunity specific to colon cancer in mice.
Authors: Michele Del Vecchio; Emilio Bajetta; Stefania Canova; Michael T Lotze; Amy Wesa; Giorgio Parmiani; Andrea Anichini Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Koji Kono; Akihiro Takahashi; Hidemitsu Sugai; Hideki Fujii; A Raja Choudhury; Rolf Kiessling; Yoshiro Matsumoto Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: J Mu; J P Zou; N Yamamoto; T Tsutsui; X G Tai; M Kobayashi; S Herrmann; H Fujiwara; T Hamaoka Journal: Cancer Res Date: 1995-10-01 Impact factor: 12.701
Authors: Tomasz Switaj; Ahmad Jalili; Anna B Jakubowska; Nadzieja Drela; Magdalena Stoksik; Dominika Nowis; Grzegorz Basak; Jakub Golab; Piotr J Wysocki; Andrzej Mackiewicz; Agata Sasor; Koryna Socha; Marek Jakóbisiak; Witold Lasek Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Takashi Saika; Takefumi Satoh; Nobuyuki Kusaka; Shin Ebara; Vladimir B Mouraviev; Terry L Timme; Timothy C Thompson Journal: Cancer Gene Ther Date: 2004-05 Impact factor: 5.987